ArticleBMC oral health2026
Pre-vascularized enhances therapeutic effects of human bone marrow-derived mesenchymal stem cell sheets in Buccal Mucosa wound.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLesions of the buccal mucosa impair normal oral function and are often accompanied by pain. While biomaterials has demonstrated potential in promoting wound healing, its efficacy may be limited by insufficient early vascularization. This study was conducted to investigate the oral mucosa repair efficacy and regenerative potential of human bone marrow-derived mesenchymal stem cell sheets (HCS) and pre-vascularized HCS (PHCS).
methodA total of 105 rats were randomly assigned to one of three groups based on the type of graft applied to the wound bed: (1) control group: biomembranes alone, (2) HCS group: biomembranes combined with HCS, and (3) PHCS group: biomembranes combined with PHCS. HCS and PHCS were respectively combined with biomembranes and applied to full-thickness buccal mucosal wounds in rats. The wounds were observed at days 3, 5, 7, 10, and 13 post-operation and Hematoxylin and eosin staining and Masson’s Trichrome staining were conducted.
resultsCompared with the biomembrane-only control group, both HCS and PHCS treatments significantly reduced mucosal contraction and improved wound appearance. The PHCS group exhibited the least bleeding and necrosis, minimal inflammatory cell infiltration, and the highest level of early-stage revascularization. This led to the establishment of a robust microcirculation, supporting graft survival and tissue regeneration. Furthermore, PHCS grafts resulted in the thinnest epithelial layer, indicative of more favorable healing outcomes.
conclusionThe study suggest that the combination of biomembranes and PHCS implantation further improve regenerative outcomes by providing a richer source of angiogenic factors and preformed microvascular structures, therefore presents a promising therapeutic strategy for the regeneration of full-thickness buccal mucosal defects. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.